Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.59
+4.32 (2.10%)
AAPL  272.61
+6.43 (2.42%)
AMD  215.92
+19.32 (9.83%)
BAC  50.45
-0.62 (-1.21%)
GOOG  311.67
-0.02 (-0.01%)
META  640.53
+3.28 (0.51%)
MSFT  386.78
+2.31 (0.60%)
NVDA  193.22
+1.67 (0.87%)
ORCL  145.16
+3.85 (2.72%)
TSLA  404.46
+4.63 (1.16%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.